Loading data for CADL — first visit, this takes a few seconds.

Preisalarm

Candel Therapeutics Inc. (CADL)

NasdaqGM: CADL · Echtzeitkurs · USD

12.05

-0.11 (-0.90%)

Zum Schluss: Aug 19, 2026, 3:59 PM

12.50

+1.21%

Nachbörslich: 4:56 PM

-0.90% (1D)

Geld	7.49
Marktkapitalisierung	945 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-88.53 Mio
Beta	-0.50
EPS (ttm)	-1.47
KGV (TTM)	n/a
Forward-KGV	-19.76
KBV (TTM)	7.45
KUV (TTM)	n/a
Earnings Date	Nov 12, 2026

Brief	13.51
Volumen	786,293
Ø Vol. (20D)	1,647,104
Eröffnung	11.92
Vortagesschluss	12.16
Tagesspanne	11.77 - 12.15
52-Wk Range	4.35 - 12.48
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develo...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Jul 27, 2021

Mitarbeiter 55

Börse NasdaqGM

Tickersymbol CADL

Website https://www.candeltx.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Candel Therapeutics 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -38.18 Mio, ein Rückgang von -30.8 %.

Finanzberichte

Gewinnüberraschung

Candel Therapeutics hat die Quartalszahlen am Aug 13, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.36 verfehlt die Erwartungen um -0.13, mit -80.00% Rückgang im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Candel Therapeutics Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 12, 2026, vor Börseneröffnung.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 6 Tagen · Stocktwits

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4

If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.

vor 1 Woche · Stocktwits

CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity

Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.

vor 1 Woche · MarketBeat

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up

Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief S...

vor 1 Monat · Stocktwits

CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’

Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.

vor 1 Monat · Exec Edge

Candel Therapeutics Designates Mark Sims as CCO

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Gl...

Seite 1 von 2

Candel Therapeutics Inc. (CADL)